{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T06:31:37Z","timestamp":1786516297947,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      SH-1028 is an irreversible third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) developed for treating locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring\n                      <jats:italic>EGFR<\/jats:italic>\n                      T790M mutation. This study aimed to systematically investigate the absorption, distribution, metabolism and excretion (ADME) profiles of SH-1028 in rats and humans using a [\n                      <jats:sup>14<\/jats:sup>\n                      C] radiolabeled tracer.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This integrated preclinical and clinical investigation comprised a radiolabeled mass balance study with quantitative whole-body autoradiography (QWBA) in rats, followed by a human mass balance study of [\n                      <jats:sup>14<\/jats:sup>\n                      C]SH-1028. Blood, urine and fecal samples were collected at predefined time points or intervals. Plasma pharmacokinetics, mass balance, metabolite profiling, and structural identification of major metabolites were assessed. Safety was also evaluated throughout the clinical phase.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Following a single oral dose of [\n                      <jats:sup>14<\/jats:sup>\n                      C]SH-1028 in humans, the mean total recovery of radioactivity was 85.02%, with 81.55% in feces and 3.48% in urine, indicating fecal excretion as the primary elimination pathway, which is consistent with observations in rats. Two major circulating metabolites not detected in animal studies, M541i and Imp2, were identified in human plasma, accounting for 20% and 60% of the total plasma radioactivity, respectively. The cumulative excretion of unchanged SH-1028 in urine and feces accounted for only 3.52% of the administered dose, indicating that SH-1028 undergoes extensive metabolism\n                      <jats:italic>in vivo<\/jats:italic>\n                      and is eliminated primarily as metabolites.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      SH-1028 was well tolerated in subjects after a single oral administration of 200\u00a0mg containing 3.26 MBq (88\u00a0\u03bcCi) of [\n                      <jats:sup>14<\/jats:sup>\n                      C]SH-1028. The parent drug and its metabolites M541i and Imp2 were identified as the major circulating components. Mass balance studies in both rats and humans consistently demonstrated that SH-1028 is eliminated predominantly via fecal excretion, undergoes extensive metabolism, and is cleared primarily as metabolites.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1897957","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:59:25Z","timestamp":1786514365000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Absorption, distribution, metabolism, and excretion of [14C]SH-1028, a third-generation EGFR-TKI, in rats and humans"],"prefix":"10.3389","volume":"17","author":[{"given":"Sufeng","family":"Zhou","sequence":"first","affiliation":[{"name":"Phase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Clinical Pharmacology, Pharmacy College, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Wu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Clinical Pharmacology, Pharmacy College, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Xie","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quankun","family":"Zhuang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chen","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhu","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Nanjing Sanhome Pharmaceutical Co., Ltd.","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shao","sequence":"additional","affiliation":[{"name":"Phase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University","place":["Nanjing, China"]},{"name":"Department of Clinical Pharmacology, Pharmacy College, Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1158\/1538-7445.am2016-3063","article-title":"Discovery of a third-generation EGFR inhibitor, which is highly selective and potent against both resistant and activating EGFR mutations for NSCLC therapy","volume":"76","author":"Bao","year":"2016","journal-title":"Cancer Res."},{"key":"B2","unstructured":"Technical guideline for radiolabeled human mass balance studies\n          \n          \n          2024"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.115.069203","article-title":"Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor","author":"Dickinson","year":"2016"},{"key":"B4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/S1470-2045(19)30690-4","article-title":"Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials","volume":"21","author":"Drilon","year":"2020","journal-title":"Lancet. Oncol."},{"key":"B5","article-title":"Part 361-Prescription drugs for human use generally recognized as safe and effective and not misbranded: drugs used in research. Title 21, code of federal regulations","year":"2002"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"665253","DOI":"10.3389\/fphar.2021.665253","article-title":"SH-1028, an irreversible third-generation EGFR TKI, overcomes T790M-Mediated resistance in non-small cell lung cancer","volume":"12","author":"Han","year":"2021","journal-title":"Front. Pharmacology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1002\/cncr.34697","article-title":"Safety, efficacy, and pharmacokinetics of SH-1028 in EGFR T790M-positive advanced non-small cell lung cancer patients: a dose-escalation phase 1 study","volume":"129","author":"He","year":"2023","journal-title":"Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","article-title":"The biology and management of non-small cell lung cancer","volume":"553","author":"Herbst","year":"2018","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1021\/js970486q","article-title":"Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening","volume":"87","author":"Hop","year":"1998","journal-title":"J. Pharmaceutical Sciences"},{"key":"B11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The effect of advances in lung-cancer treatment on population mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. Journal Medicine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0146-6453(87)90003-0","article-title":"Radiation dose to patients from radiopharmaceuticals","volume":"18","year":"1988","journal-title":"Ann. ICRP"},{"key":"B13","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.critrevonc.2020.103194","article-title":"Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives","volume":"157","author":"Imyanitov","year":"2021","journal-title":"Crit. Reviews Oncology\/hematology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.tips.2016.09.003","article-title":"EGFR as a pharmacological target in EGFR-mutant non-small-cell lung cancer: where do we stand now?","volume":"37","author":"Ke","year":"2016","journal-title":"Trends Pharmacological Sciences"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.02.001","article-title":"Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures","volume":"174","author":"Lee","year":"2017","journal-title":"Pharmacol. and Therapeutics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.lungcan.2017.09.005","article-title":"Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs","volume":"113","author":"Lee","year":"2017","journal-title":"Lung Cancer Amsterdam, Neth."},{"key":"B17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3349\/ymj.2022.63.9.799","article-title":"Lazertinib: on the way to its throne","volume":"63","author":"Lee","year":"2022","journal-title":"Yonsei Medical Journal"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9476","DOI":"10.1111\/jcmm.16897","article-title":"Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: a case series and literature review","volume":"25","author":"Li","year":"2021","journal-title":"J. Cellular Molecular Medicine"},{"key":"B19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10637-023-01356-5","article-title":"Drug-drug interaction potential of SH-1028, a third-generation EGFR-TKI: in vitro and clinical trials","volume":"41","author":"Li","year":"2023","journal-title":"Investig. New Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/jco.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib Versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J. Clinical Oncology Official Journal Am. Soc. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4065\/83.5.584","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin. Proceedings"},{"key":"B22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1080\/03602532.2016.1181081","article-title":"Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review","volume":"48","author":"Nijenhuis","year":"2016","journal-title":"Drug Metab. Reviews"},{"key":"B23","doi-asserted-by":"publisher","first-page":"vdab188","DOI":"10.1093\/noajnl\/vdab188","article-title":"Osimertinib in advanced EGFR-mutant lung adenocarcinoma with asymptomatic brain metastases: an open-label, 3-arm, phase II pilot study","volume":"4","author":"Peled","year":"2021","journal-title":"Neuro-oncology Advances"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9602","article-title":"Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: a phase IIb multicenter single-arm study","author":"Shi","year":"2020"},{"key":"B25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/nejmoa1713137","article-title":"Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. Journal Medicine"},{"key":"B26","article-title":"Safety testing of drug metabolites: guidance for industry (revision 2)","volume-title":"U.S. Department of Health and Human Services, Food and Drug Administration","year":"2020"},{"key":"B27","unstructured":"Clinical pharmacology considerations for human radiolabeled mass balance studies: guidance for industry\n          \n          \n          2024"},{"key":"B28","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1177\/0271678X19843776","article-title":"A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib - a drug intended for treatment of brain metastases in non-small cell lung cancer","volume":"40","author":"Varrone","year":"2020","journal-title":"J Cereb Blood Flow Metab."},{"key":"B29","doi-asserted-by":"publisher","first-page":"7025","DOI":"10.1021\/jm400822z","article-title":"Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)","volume":"56","author":"Ward","year":"2013","journal-title":"J. Medicinal Chemistry"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jtho.2022.06.013","article-title":"Efficacy and safety of SH-1028 in patients with EGFR T790M-Positive NSCLC: a multicenter, single-arm, open-label, phase 2 trial","volume":"17","author":"Xiong","year":"2022","journal-title":"J. Thoracic Oncology Official Publication Int. Assoc. Study Lung Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"102557","DOI":"10.1016\/j.ctrv.2023.102557","article-title":"Acquired resistance mechanisms to osimertinib: the constant battle","volume":"116","author":"Zalaquett","year":"2023","journal-title":"Cancer Treatment Reviews"},{"key":"B32","doi-asserted-by":"publisher","first-page":"288","DOI":"10.21037\/tlcr.2016.06.07","article-title":"Non-small cell lung cancer: current treatment and future advances","volume":"5","author":"Zappa","year":"2016","journal-title":"Transl. Lung Cancer Research"},{"key":"B33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1080\/00498254.2023.2183367","article-title":"Development and validation of an LC-MS\/MS method for simultaneous determination of SH-1028, an irreversible third-generation EGFR TKI, and two of its metabolites in human plasma: application in clinical pharmacokinetics","volume":"53","author":"Zhou","year":"2023","journal-title":"Xenobiotica; Fate Foreign Compounds Biological Systems"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1897957\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:59:27Z","timestamp":1786514367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1897957\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":33,"alternative-id":["10.3389\/fphar.2026.1897957"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1897957","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1897957"}}